Finance

Lists
IMVT:NASDAQ
Immunovant Inc
$38.10
-1.68%
(-0.65) 1D
$38.15
+0.13% (+0.050)
Pre-market
Closed: Sep 10, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IMVT...
Open
$38.18
High
$38.30
Low
$37.52
Mkt. cap
7.87B
Avg. vol.
1.15M
Volume
50.00
52-wk high
$45.35
52-wk low
$14.58
EPS
-$2.81
Beta
0.81
Shares outstanding
206.55M
No. of employees
315
Open
$38.18
High
$38.30
Low
$37.52
Mkt. cap
7.87B
Avg. vol.
1.15M
Volume
50.00
52-wk high
$45.35
52-wk low
$14.58
EPS
-$2.81
Beta
0.81
Shares outstanding
206.55M
No. of employees
315
News stories
From web sources and news partners
About Immunovant Inc
CEO-
Employees315
Founded2018
Headquarters-
SectorBiotechnology
Websiteimmunovant.com
Analyst ratings
Based on 10 analysts giving stock ratings to IMVT in the past 3 months
Strong buy
Buy
8
Hold
2
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for IMVT in the last 3 months.
Highest
Current $38.10
$66.00 (+73.23%)
Average
$49.70 (+30.45%)
Lowest
$30.00 (-21.26%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
UBS
Hold
Reiterated
$40.00
+5%
08/24/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
$57.00
+49.6%
08/11/2026
Brian Cheng
J.P. Morgan
Buy
Maintained
$50.00
+31.2%
08/10/2026
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
$41.00
+7.6%
08/10/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
$54.00
+41.7%
08/07/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$53.00
+39.1%
08/07/2026
Danielle Brill
Truist Financial
Hold
Maintained
$30.00
-21.3%
08/07/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$66.00
+73.2%
08/07/2026
Dina Ramadane
Bank of America Securities
Buy
Reiterated
$45.00
+18.1%
08/07/2026
Samantha Semenkow
Citi
Buy
Maintained
$61.00
+60.1%
06/30/2026
Yatin Suneja
Guggenheim
Buy
Maintained
$62.00
+62.7%
05/26/2026
Jason Gerberry
Bank of America Securities
Buy
Maintained
$43.00
+12.9%
05/21/2026
Derek Archila
Wells Fargo
Buy
Reiterated
$45.00
+18.1%
05/21/2026
Corinne Johnson
Goldman Sachs
Hold
Reiterated
$32.00
-16%
04/15/2026
Andy Chen
Wolfe Research
Buy
Maintained
$47.00
+23.4%
04/06/2026
Thomas Smith
Leerink Partners
Buy
Reiterated
$50.00
+31.2%
04/02/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
$45.00
+18.1%
04/01/2026
William Pickering
Bernstein
Hold
Initiated
$28.00
-26.5%
03/20/2026
Last report
Aug 6, 2026
Fiscal period
Q1 2027
EPS / Est. (USD)
-$0.75 / -$0.61
-22.21%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
114.25M
98.92M
142.29M
142.63M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
17.51M
15.44M
17.27M
17.69M
Operating expense
131.76M
114.36M
159.55M
160.32M
Total operating expenses
131.76M
114.36M
159.55M
160.32M
Operating income
-131.76M
-114.36M
-159.55M
-160.32M
Other non operating income
250.00K
-54.00K
798.00K
4.00K
EBT including unusual items
-125.91M
-109.08M
-150.70M
-153.22M
EBT excluding unusual items
-125.91M
-109.08M
-150.70M
-153.22M
Income tax expense
594.00K
1.55M
-2.84M
-
Effective tax rate
-0.47%
-1.42%
1.89%
-
Other operating expenses
-
-
-
-
Net income
-126.50M
-110.64M
-147.86M
-153.22M
Net profit margin
-
-
-
-
Earnings per share
-0.65
-0.54
-0.67
-0.68
Interest and investment income
5.60M
5.33M
8.06M
7.10M
Interest expense
-
-
-
-
Net interest expenses
5.60M
5.33M
8.06M
7.10M
Depreciation and amortization charges
-
-
-
-
EBITDA
-131.66M
-114.26M
-159.46M
-160.23M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps